Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-01-27

FDA Approved: EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Aurobindo Pharma Limited)

View source ↗

Summary

FDA approved a supplemental application for a generic fixed-dose combination of efavirenz, emtricitabine, and tenofovir disoproxil fumarate used to treat HIV-1 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (Efavirenz; Emtricitabine; Tenofovir disoproxil fumarate)

Snippet

SUPPL AP for EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)